Safety and efficacy of mycophenolate in COVID-19: a nonrandomised prospective study in western India

作者：Atul Sajgure, Atul Sajgure, Ajit R. Kulkarni, Atul Joshi, Vasanti Sajgure, Vaishali Pathak, Rashida Patanwala Melinkeri, Shilpa Pathak, Sumit Agrawal, Manoj Kumar Naik, Milind Rajurkar, Ameya Sajgure, Ameya Sajgure, Girish Date · 发表于：The Lancet Regional Health - Southeast Asia · 年份：2023 · DOI：10.1016/j.lansea.2023.100154 · 被引用次数：15 · 研究领域：COVID-19 Clinical Research Studies、SARS-CoV-2 and COVID-19 Research、Immune responses and vaccinations

Background: Antivirals and immunosuppressive agents are used with variable success in the treatment of COVID-19. Mycophenolate, an inhibitor of enzyme inosine monophosphate dehydrogenase, is an immunosuppressant used to prevent allograft rejection and other autoimmune diseases. Few laboratory studies have also reported antiviral properties of mycophenolate. The current study tried to assess the safety and efficacy of mycophenolate in patients hospitalised with COVID-19. Methods: This was a prospective non-randomised open label study with the objective to assess the effect of addition of mycophenolate to the standard of care on mortality due to COVID-19 and duration of hospital stay. The target study population was comprised of patients requiring inpatient treatment for COVID-19 during the period from Jan 15-April 15, 2021. The study was registered with Clinical Trial Registry of India (CTRI/2021/01/030477, registered on date-14/01/2021). Adult patients (n = 106) requiring hospitalisation for COVID-19 received mycophenolate, 360 mg, one tablet daily for one month. Mycophenolate was initiated within 48 h of the diagnosis of SARS-CoV-2 infection by RT‒PCR. While patients who did not consent for mycophenolate (n = 106), received only standard of care, and were considered as control group. The relevant clinical data including NEWS2 scores and high-resolution computed tomography of the thorax were collected and analysed. Findings: The mortality and hospital stay were significantly ...